Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial

alexandrossfakianakis shared this article with you from Inoreader Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial via ScienceDirect Publication: The Lancet Infectious Diseases Publication date: Available online 13 June 2022 Source: The Lancet Infectious Diseases Author(s): Sean R Bennett, James M McCarty, Roshan Ramanathan, Jason Mendy, Jason S Richardson, Jonathan Smith, Jeff Alexander, Julie E Ledgerwood, Paul-André de Lame, Sarah Royalty Tredo, Kelly L Warfield, Lisa Bedell View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.